Gene therapy (e.g., onasemnogene abeparvovec for spinal muscular atrophy) used to deliver a functional copy of the SMN1 gene to replace the defective gene in spinal muscular atrophy (SMA) has shown clinical benefits (Ogbonmide et al., 2023). This evidence concerns the gene SMN1 and spinal muscular atrophy.